

Ministry of Health

OHIP, Pharmaceuticals and Devices Division

Drug Submission Status

Report for March 2022

Complete Streamlined Multiple-Source Submissions for Future Formulary Listing

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for listing on the Ontario Drug Benefit Formulary. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be listed as benefits in a future Formulary update. Final listing status will be communicated when the Formulary update is published on the Ministry website and via a OPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Sanis Health Inc.	Alfuzosin	Xatral	ALFUZOSIN HYDROCHLORIDE	10 mg	ER tablet	02519844
Auro Pharma Inc.	Auro-Silodosin	Rapaflo	SILODOSIN	4 mg	capsule	02478501
Auro Pharma Inc.	Auro-Silodosin	Rapaflo	SILODOSIN	8 mg	capsule	02478528
Sanis Health Inc.	Clindamycin	Dalacin	CLINDAMYCIN HCL	150 mg	capsule	02400529
Sanis Health Inc.	Clindamycin	Dalacin	CLINDAMYCIN HCL	300 mg	capsule	02400537

Generic Medical Partners Inc.	Med-Clindamycin	Dalacin C	CLINDAMYCIN HCL	150 mg	capsule	02462656
Generic Medical Partners Inc.	Med-Clindamycin	Dalacin C	CLINDAMYCIN HCL	300 mg	capsule	02462664
Mantra Pharma Inc.	M-Metronidazole	Flagyl	METRONIDAZOLE	500 mg	capsule	02519755
Auro Pharma Inc.	Auro-Amoxiclav	Clavulin	AMOXICILLIN & CLAVULANIC ACID	250 mg/125 mg	tablet	02471671
Auro Pharma Inc.	Auro-Amoxiclav	Clavulin	AMOXICILLIN & CLAVULANIC ACID	500 mg/125 mg	tablet	02471698
Auro Pharma Inc.	Auro-Amoxiclav	Clavulin (BID)	AMOXICILLIN & CLAVULANIC ACID	875 mg/125 mg	tablet	02471701